Nevada Medicaid and Nevada Check Up News (First Quarter 2024 Provider Newsletter) [Read]

Attention Behavioral Health Providers: Monthly Behavioral Health Training Assistance (BHTA) Webinar Scheduled [See Web Announcement 2009]

Attention All Providers: Requirements on When to Use the National Provider Identifier (NPI) of an Ordering, Prescribing or Referring (OPR) Provider on Claims [Announcement 850]

If you are a Medicaid provider whose revalidation application has not been processed by your termination due date, you will be ineligible to provide services to any Nevada Medicaid or Nevada Check Up recipients, including both Fee-for-Service and Managed Care Organization (MCO) enrolled recipients. See Web Announcement 1265

Enrollment Termination Frequently Asked Questions (FAQs) [Review]

Notifications

NOTIFICATION: The following Nevada Medicaid Provider Web Portal services will be unavailable from 10 p.m. to midnight Pacific Time Saturday, June 29, 2024, for scheduled maintenance:
  • Real time CAQH/CORE EDI eligibility and claim verification

NOTIFICATION: The following Nevada Medicaid Provider Web Portal services will be unavailable from 8 p.m. to midnight Pacific Time Sunday, June 30, 2024, for scheduled maintenance:
  • Secure Provider Web Portal (Electronic Verification System – EVS), which includes:
    • Recipient Eligibility
    • Provider Claim Appeals
    • Prior Authorization (PA) system
    • Claims Submission
  • Online Provider Enrollment (OPE)
  • Gabby®, which includes:
    • Customer Service Center (877) 638-3472
    • Automated Response System (ARS) (800) 942-6511
  • Real time CAQH/CORE EDI eligibility and claim verification
  • Provider PASRR

Electronic Visit Verification (EVV) Claim Update: Providers using Sandata for claims submission are advised to allow 24 hours after claim submission for claim details to be visible in the Medicaid Management Information System (MMIS). Please be advised that claims must be submitted before noon Pacific Time on Fridays to be included in the following weeks’ remittance advice.

Unwinding COVID-19 Information

Known System Issues-Click HERE

Feedback Requested Regarding the Gabby™ Interactive Voice Response (IVR) System Survey

Paper claims are no longer accepted by Nevada Medicaid. Please refer to Web Announcement 1733 and Web Announcement 1829 for additional information.

Top 10 Claim Denial Reasons and Resolutions/Workarounds for May 2024 Professional Claims. See Web Announcement 3382.

Top Enrollment Return Reasons and Resolutions for January 2024 Submissions. See Web Announcement 3350.

Top Prior Authorization Denial Reasons for the Fourth Quarter of 2023. See Web Announcement 3280.

Attention Providers Using the Authorization Criteria Function: Results that return prior authorization (PA) requirements are accurate. For results that return “There are no records found based on the search criteria,” there may be a PA requirement if limits have been exceeded. To verify PA requirements, please refer to the Medicaid Services Manual (MSM) Chapter for your service type at dhcfp.nv.gov and the Billing Guide for your provider type at www.medicaid.nv.gov.

Scheduled Site Maintenance

During the scheduled site maintenance window the Provider Web Portal will be unavailable. The table below shows the regularly scheduled maintenance window. All times will be in the Pacific time zone.

Monday - Friday
12:00AM - 12:30AM

Monday
8:00PM - 12:00AM

Notice Date Title
Oct. 15, 2014 For Review at November 13 Meeting: ADHD Agents and Stimulants
Oct. 15, 2014 For Review at November 13 Meeting: Alzheimer’s Agents
Oct. 15, 2014 For Review at November 13 Meeting: Angiotensin II Receptor Blockers (ARBs) – Combination Products
Oct. 15, 2014 For Review at November 13 Meeting: Anticonvulsants
Oct. 15, 2014 For Review at November 13 Meeting: Anticonvulsants-Benzodiazepines
Oct. 15, 2014 For Review at November 13 Meeting: Antivirals: Influenza
Oct. 15, 2014 For Review at November 13 Meeting: Benign Prostatic Hyperplasia Treatments
Oct. 15, 2014 For Review at November 13 Meeting: Beta-Agonists: Combination Products
Oct. 15, 2014 For Review at November 13 Meeting: Beta-Agonists Single Entity Agents
Oct. 15, 2014 For Review at November 13 Meeting: Bisphosphonates
Oct. 15, 2014 For Review at November 13 Meeting: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Oct. 15, 2014 For Review at November 13 Meeting: Fibric Acid Derivatives
Oct. 15, 2014 For Review at November 13 Meeting: Growth Hormone
Oct. 15, 2014 For Review at November 13 Meeting: Hepatitis C Antivirals
Oct. 15, 2014 For Review at November 13 Meeting: Immunomodulators
Oct. 15, 2014 For Review at November 13 Meeting: Incretin Mimetics
Oct. 15, 2014 For Review at November 13 Meeting: Injectable Anticoagulants
Oct. 15, 2014 For Review at November 13 Meeting: Intranasal Histamine H1-receptor Antagonists (Antihistamines)
Oct. 15, 2014 For Review at November 13 Meeting: Multiple Sclerosis Agents
Oct. 15, 2014 For Review at November 13 Meeting: Neuropathic Pain Agents
Oct. 15, 2014 For Review at November 13 Meeting: Ophthalmic Antihistamines
Oct. 15, 2014 For Review at November 13 Meeting: Ophthalmic Fluoroquinolones
Oct. 15, 2014 For Review at November 13 Meeting: Ophthalmic Nonsteroidal Anti-Inflammatory Drugs
Oct. 15, 2014 For Review at November 13 Meeting: Oral Atypical (Second-Generation) Antipsychotics
Oct. 15, 2014 For Review at November 13 Meeting: Otic Fluoroquinolones
Oct. 15, 2014 For Review at November 13 Meeting: Pancreatic Enzymes
Oct. 15, 2014 For Review at November 13 Meeting: Phosphorus Depleters
Oct. 15, 2014 For Review at November 13 Meeting: Platelet Inhibitors
Oct. 15, 2014 For Review at November 13 Meeting: Proton Pump Inhibitors
Oct. 15, 2014 For Review at November 13 Meeting: Pulmonary Arterial Hypertension Agents
Oct. 15, 2014 For Review at November 13 Meeting: Restless Legs Syndrome
Oct. 15, 2014 For Review at November 13 Meeting: Scabicides and Pediculicides
Oct. 15, 2014 For Review at November 13 Meeting: Second and Third Generation Oral Fluoroquinolones
Oct. 15, 2014 For Review at November 13 Meeting: Selective Serotonin (5-HT) 1 Receptor Agonists
Oct. 15, 2014 For Review at November 13 Meeting: Selective Serotonin Reuptake Inhibitors
Oct. 15, 2014 For Review at November 13 Meeting: Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors
Oct. 15, 2014 For Review at November 13 Meeting: Third Generation Cephalosporins
Oct. 15, 2014 For Review at November 13 Meeting: Topical Analgesics and Anesthetics
Oct. 15, 2014 For Review at November 13 Meeting: Topical Androgens
Oct. 15, 2014 For Review at November 13 Meeting: Topical Psoriasis Agents
Oct. 15, 2014 For Review at November 13 Meeting: Ulcerative Colitis Agents
Oct. 15, 2014 For Review at November 13 Meeting: Urinary Antispasmodics
Aug. 11, 2014 For Review at September 25 Meeting: ADHD Agents and Stimulants
Aug. 11, 2014 For Review at September 25 Meeting: Incretin Mimetics
Aug. 11, 2014 For Review at September 25 Meeting: Inhaled Antimuscarinics
Aug. 11, 2014 For Review at September 25 Meeting: Long-Acting Opioids
Aug. 11, 2014 For Review at September 25 Meeting: Niacin Derivatives
Aug. 11, 2014 For Review at September 25 Meeting: Psoriatic Arthritis Phosphodiesterase 4 Inhibitors
Aug. 11, 2014 For Review at September 25 Meeting: Serotonin and Norepinephrine Reuptake Inhibitors
May 13, 2014 For Review at June 26 Meeting: Angiotensin-Converting Enzyme (ACE) Inhibitors Single Entity Agents
May 13, 2014 For Review at June 26 Meeting: Anticonvulsants
May 13, 2014 For Review at June 26 Meeting: Immunomodulators
May 13, 2014 For Review at June 26 Meeting: Inhaled Antimuscarinics
May 13, 2014 For Review at June 26 Meeting: Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors
Feb. 13, 2014 For Review at March 27 Meeting: Beta Agonists Combination Products
Feb. 13, 2014 For Review at March 27 Meeting: Beta Agonists Single Entity Agents
Feb. 13, 2014 For Review at March 27 Meeting: Hepatitis C Polymerase Inhibitors
Feb. 13, 2014 For Review at March 27 Meeting: Hepatitis C Protease Inhibitors
Feb. 13, 2014 For Review at March 27 Meeting: Inhaled Corticosteroids
Feb. 13, 2014 For Review at March 27 Meeting: Pulmonary Arterial Hypertension Agents
Feb. 13, 2014 For Review at March 27 Meeting: Serotonin and Norepinephrine Reuptake Inhibitors
Feb. 13, 2014 For Review at March 27 Meeting: Serotonin Modulators

Return to Past Meeting Reports.